DEXTENZA™ (dexamethasone insert) 0.4mg IS NOW APPROVED!   BIG TIME INNOVATION   THE FIRST AND ONLY 30-DAY INTRACANALICULAR STEROID INSERT*       DEXTENZA is a corticosteroid indicated for the treatment of ocular pain following ophthalmic surgery.       • Physician inserted for control over delivery and dosing1   • Drug release tapers over time2   • Frees patients from complicated steroid drop regimens1,3,4   • Contains no preservatives1   • Conjugated with fluorescein for visualization1       View press release.       Care should be taken when inserting DEXTENZA. See the Dosage and Administration section of the full Prescribing Information.       * DEXTENZA is an intracanalicular insert releasing a 0.4 mg dose of dexamethasone without preservatives for up to 30 days following insertion.       IMPORTANT SAFETY INFORMATION       Contraindications       DEXTENZA™ is contraindicated in patients with active cornea, conjunctiva or canalicular infections, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella; mycobacterial infections; fungal diseases of the eye, and dacryocystitis.       Warnings and Precautions       Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma and intraocular pressure should be monitored during treatment.       Corticosteroids may suppress the host response and thus increase the hazard for secondary ocular infections. In acute purulent conditions, steroids may mask infection and enhance existing infection. Use of ocular steroids may prolong the course and may exacerbate the severity of viral infections of the eye (including herpes simplex).       Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate.       Use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.       Adverse Reactions       The most common ocular adverse reactions that occurred in patients treated with DEXTENZA were: anterior chamber inflammation, iritis, intraocular pressure increased, visual acuity reduced, eye pain, cystoid macular edema, corneal edema, and conjunctival hyperemia.       The most common non-ocular adverse reaction that occurred in patients treated with DEXTENZA was headache.       References: 1. DEXTENZA [package insert]. Bedford, MA: Ocular Therapeutix Inc; 2017. 2. Blizzard C, Desai A, Driscoll A. Pharmacokinetic studies of sustained-release depot of dexamethasone in beagle dogs. J Ocul Pharmacol Ther. 2016;32(9):595-600. 3. Durezol [package insert]. Fort Worth, TX: Novartis; 2016. 4. Lotemax gel [package insert]. Bridgewater, NJ: Bausch & Lomb Inc; 2016.     Privacy Policy  |  Contact Us   Click here to see the full Prescribing Information for DEXTENZA.   Ocular Therapeutix Bed‍ford, MA 0‍1730   © 2017 Ocular Therapeutix, Inc. All rights reserved. DEXTENZA is a trademark of Ocular Therapeutix, Inc. PP‑US‑DX‑0033